PROMETRIUM CAPSULE

Kraj: Kanada

Język: angielski

Źródło: Health Canada

Kup teraz

Składnik aktywny:

PROGESTERONE

Dostępny od:

ORGANON CANADA INC.

Kod ATC:

G03DA04

INN (International Nazwa):

PROGESTERONE

Dawkowanie:

100MG

Forma farmaceutyczna:

CAPSULE

Skład:

PROGESTERONE 100MG

Droga podania:

ORAL

Sztuk w opakowaniu:

28/100

Typ recepty:

Prescription

Dziedzina terapeutyczna:

PROGESTINS

Podsumowanie produktu:

Active ingredient group (AIG) number: 0106327002; AHFS:

Status autoryzacji:

APPROVED

Data autoryzacji:

2011-02-17

Charakterystyka produktu

                                Page 1 of 34
PRODUCT MONOGRAPH
PROMETRIUM
®
Progesterone capsules
100 mg
Progestin
Organon Canada Inc.
16766 route Transcanadienne
Kirkland QC Canada H9H 4M7
www.organon.ca
Date of Revision:
March 29, 2021
Submission Control No: 249484
_ _
_ _
Page 2 of 34
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................10
DRUG INTERACTIONS
..................................................................................................15
DOSAGE AND ADMINISTRATION
..............................................................................16
OVERDOSAGE
................................................................................................................16
ACTION AND CLINICAL PHARMACOLOGY
............................................................17
STORAGE AND STABILITY
..........................................................................................19
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................19
PART II: SCIENTIFIC INFORMATION
...............................................................................20
PHARMACEUTICAL INFORMATION
..........................................................................20
CLINICAL TRIALS
..........................................................................................................21
TOXICOLOGY
..............................................................................................................
                                
                                Przeczytaj cały dokument
                                
                            

Dokumenty w innych językach

Charakterystyka produktu Charakterystyka produktu francuski 29-03-2021

Wyszukaj powiadomienia związane z tym produktem

Zobacz historię dokumentów